A novel clinically applicable biomarker for testing HRD status based on the mutational signatures: Results for the phase 2 trial of olaparib maintenance monotherapy in patients with primary high-grade ovarian carcinoma (2271)Katsutoshi Oda, Hiroyuki Aburatani, Akira Nishijima et al.|Gynecologic Oncology|2023Cited by 0
777P A phase II study of the efficacy of olaparib maintenance monotherapy for patients with HRD-positive, newly diagnosed, advanced, high-grade ovarian cancer, evaluated by whole-exome sequencing (MSBM-OL)Katsutoshi Oda, K. Hasegawa, Daisuke Shintani et al.|Annals of Oncology|2024Cited by 0
Mutational Signature‐Based Biomarker for Phase <scp>II</scp> Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian CancerKatsutoshi Oda, Kosei Hasegawa, Noriomi Matsumura et al.|Cancer Science|2026Cited by 0